Showing 1 - 7 of 7 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ciclesonide is a glucocorticoid receptor agonist indicated for the treatment of allergic rhinitis (Omnaris nasal spray) and asthma (Alvesco). It was also developed by Byk Gulden for chronic obstructive pulmonary disease (COPD), but no development had...
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Zardaverine (6-(4-difluoromethoxy-3-methoxyphenyl)-3[2H]pyridazinone) is a dual-selective inhibitor of phosphodiesterase III/IV was developed as a potential therapeutic agent for asthma. Zardaverine has been shown to inhibit inflammatory cell functio...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Urapidil is an anti-hypertensive agent approved in Europe for the treatment of the corresponding disease. The drug acts by activating 5HT1a receptor and inhibiting alpha1-adrenergic receptors.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-...
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Urapidil is an anti-hypertensive agent approved in Europe for the treatment of the corresponding disease. The drug acts by activating 5HT1a receptor and inhibiting alpha1-adrenergic receptors.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Urapidil is an anti-hypertensive agent approved in Europe for the treatment of the corresponding disease. The drug acts by activating 5HT1a receptor and inhibiting alpha1-adrenergic receptors.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-...